Repeated-Dose High-Dose Ivermectin Pharmacokinetics and Safety in Children with Acute Dengue (2026)

Peer-Reviewed Study · Lapphra K, Mairiang D, Tarning J, Prayongkul D, Puttikhunt C, Songjaeng A, et al. · 2026

Lapphra K et al., 2026: Prospective open-label sequential dose-escalation study giving 400 or 600 mcg/kg of ivermectin once daily for three days to children with acute dengue in Thailand. It supplies recent repeated-dose exposure and safety data in a paediatric population.

children aged 1-15 years who presented within 72 h of fever onset and met the protocol laboratory-confirmation criteria for dengue received ivermectin 400 or 600 μg/kg once daily for 3 days

Lapphra K et al., 2026: Prospective open-label sequential dose-escalation study giving 400 or 600 mcg/kg of ivermectin once daily for three days to children with acute dengue in Thailand. It supplies recent repeated-dose exposure and safety data in a paediatric population. C2 repeated-dose, latest data. Study type: prospective, open-label, sequential dose-escalation phase II study (ClinicalTrials.gov NCT03432442); N not stated in the abstract captured; Thailand (Siriraj Hospital, Mahidol University, Bangkok). Dose: ivermectin 400 or 600 mcg/kg once daily for 3 days, oral. Comparator: none (sequential dose escalation). Funder: Siriraj Hospital / Mahidol University faculty research grants (R016136003, R016634008). Declared conflicts: 'The authors declare that they have no competing interests.' The authors state the study 'was not designed to determine antiviral efficacy or clinical benefit'. Study type: uncontrolled series.